DocDollars

Mylan Pharmaceuticals Inc.

WV · United States · Reporting entity ID 100000005572

Total reported 2019–2025
$26.9M
#262 of 2,960 reporting companies — 0% of all reported industry payments
$414K in general payments across 16,623 records, plus $26.5M in research funding across 364 records.

How it breaks down

General payments $413,589
Research funding $26,487,237

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Mylan Pharmaceuticals Inc. reported $26.9M to US doctors and teaching hospitals from 2019 to 2025, ranking #262 of 2,960 reporting companies. 98% of that was research funding and 2% general payments such as consulting, speaking, food and travel. 16,623 general payment records and 364 research records were filed.

Common questions about Mylan Pharmaceuticals Inc.

How much has Mylan Pharmaceuticals Inc. paid US doctors?

Mylan Pharmaceuticals Inc. reported $26,900,826 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $413,589 in general payments, $26,487,237 in research funding.

How does Mylan Pharmaceuticals Inc. rank among drug and device companies?

It ranks #262 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Mylan Pharmaceuticals Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.